Literature DB >> 23483201

Effects of treatment with a carbon monoxide-releasing molecule and a heme oxygenase 1 inducer in the antinociceptive effects of morphine in different models of acute and chronic pain in mice.

Arnau Hervera1, Gemma Gou, Sergi Leánez, Olga Pol.   

Abstract

RATIONALE: Treatment with a carbon monoxide-releasing molecule (tricarbonyldichlororuthenium(II) dimer, CORM-2) or a classical heme oxygenase 1 inducer (cobalt protoporphyrin IX, CoPP) has potent anti-inflammatory effects, but the role played by these treatments in the antinociceptive effects of morphine during acute and chronic pain was not evaluated.
OBJECTIVES: In wild type (WT), neuronal (NOS1-KO), or inducible (NOS2-KO) nitric oxide synthases knockout mice, we evaluated the effects of CORM-2 and CoPP treatments in the antinociceptive actions of morphine and their interaction with nitric oxide during acute, visceral, and chronic inflammatory or neuropathic pain.
METHODS: Acute and visceral pain was assessed through formalin and acid acetic writhing tests. Chronic inflammatory pain induced by the intra-articular administration of complete Freund's adjuvant and neuropathic pain by partial ligation of sciatic nerve were evaluated by measuring allodynia and hyperalgesia using the von Frey filaments, plantar, or cold plate tests.
RESULTS: While nitric oxide, synthetized by NOS1 and/or NOS2, increased the local antinociceptive effects of morphine during acute and chronic pain, it decreased the inhibitory effects of morphine after visceral pain. Moreover, while CORM-2 or CoPP treatments did not alter or reduced the antinociceptive effects of morphine during acute and visceral pain, both treatments improved the local antiallodynic and antihyperalgesic effects of morphine after chronic inflammatory or neuropathic pain in WT, but not in KO mice.
CONCLUSIONS: CORM-2 and CoPP treatments improved the local antinociceptive effects of morphine during chronic inflammatory and neuropathic pain by interaction with nitric oxide synthetized by NOS1 and NOS2 isoforms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23483201     DOI: 10.1007/s00213-013-3053-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  The role of heme oxygenase in neuropathic and incisional pain.

Authors:  X Li; J D Clark
Journal:  Anesth Analg       Date:  2000-03       Impact factor: 5.108

2.  Inhibition of nitric oxide synthase enhances antinociception mediated by mu, delta and kappa opioid receptors in acute and prolonged pain in the rat spinal cord.

Authors:  H Machelska; D Labuz; R Przewłocki; B Przewłocka
Journal:  J Pharmacol Exp Ther       Date:  1997-08       Impact factor: 4.030

3.  GPR3 orphan receptor is involved in neuropathic pain after peripheral nerve injury and regulates morphine-induced antinociception.

Authors:  Jessica Ruiz-Medina; Catherine Ledent; Olga Valverde
Journal:  Neuropharmacology       Date:  2011-02-23       Impact factor: 5.250

4.  The CO-releasing molecule CORM-3 protects against articular degradation in the K/BxN serum transfer arthritis model.

Authors:  Nuria Maicas; Maria Luisa Ferrándiz; Isabel Devesa; Roberto Motterlini; Marije I Koenders; Wim B van den Berg; Maria José Alcaraz
Journal:  Eur J Pharmacol       Date:  2010-02-23       Impact factor: 4.432

Review 5.  Carbon monoxide: a gas that modulates nociception.

Authors:  Wenguo Fan; Fang Huang; Zhi Wu; Xiao Zhu; Dongpei Li; Hongwen He
Journal:  J Neurosci Res       Date:  2011-03-21       Impact factor: 4.164

6.  Development and expression of neuropathic pain in CB1 knockout mice.

Authors:  Anna Castañé; Evelyne Célérier; Miquel Martín; Catherine Ledent; Marc Parmentier; Rafael Maldonado; Olga Valverde
Journal:  Neuropharmacology       Date:  2005-09-19       Impact factor: 5.250

7.  The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2 receptors during neuropathic pain in mice.

Authors:  Arnau Hervera; Roger Negrete; Sergi Leánez; Jesús Martín-Campos; Olga Pol
Journal:  J Pharmacol Exp Ther       Date:  2010-05-24       Impact factor: 4.030

8.  Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.

Authors:  Sergi Leánez; Arnau Hervera; Olga Pol
Journal:  Eur J Pharmacol       Date:  2008-11-18       Impact factor: 4.432

9.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

10.  Nrf2-mediated haeme oxygenase-1 up-regulation induced by cobalt protoporphyrin has antinociceptive effects against inflammatory pain in the formalin test in mice.

Authors:  Angelo O Rosa; Javier Egea; Silvia Lorrio; Ana I Rojo; Antonio Cuadrado; Manuela G López
Journal:  Pain       Date:  2007-10-26       Impact factor: 6.961

View more
  13 in total

Review 1.  Carbon monoxide and the CNS: challenges and achievements.

Authors:  Cláudia S F Queiroga; Alessandro Vercelli; Helena L A Vieira
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

2.  The role of carbon monoxide on the anti-nociceptive effects and expression of cannabinoid 2 receptors during painful diabetic neuropathy in mice.

Authors:  Sílvia Castany; Mireia Carcolé; Sergi Leánez; Olga Pol
Journal:  Psychopharmacology (Berl)       Date:  2016-03-29       Impact factor: 4.530

3.  The induction of the transcription factor Nrf2 enhances the antinociceptive effects of delta-opioid receptors in diabetic mice.

Authors:  Christina McDonnell; Sergi Leánez; Olga Pol
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

4.  The Inhibitory Effects of Cobalt Protoporphyrin IX and Cannabinoid 2 Receptor Agonists in Type 2 Diabetic Mice.

Authors:  Christina McDonnell; Sergi Leánez; Olga Pol
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

5.  Spinal Nrf2 translocation may inhibit neuronal NF-κB activation and alleviate allodynia in a rat model of bone cancer pain.

Authors:  Jie Fu; Chaobo Ni; Hua-Dong Ni; Long-Sheng Xu; Qiu-Li He; Huan Pan; Dong-Dong Huang; Yan-Bao Sun; Ge Luo; Ming-Juan Liu; Ming Yao
Journal:  J Neurochem       Date:  2021-07-31       Impact factor: 5.546

Review 6.  Epigenetic modification of DRG neuronal gene expression subsequent to nerve injury: etiological contribution to complex regional pain syndromes (Part I).

Authors:  Fuzhou Wang; George B Stefano; Richard M Kream
Journal:  Med Sci Monit       Date:  2014-06-25

7.  The Induction of Heme Oxygenase 1 Decreases Painful Diabetic Neuropathy and Enhances the Antinociceptive Effects of Morphine in Diabetic Mice.

Authors:  Sílvia Castany; Mireia Carcolé; Sergi Leánez; Olga Pol
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

8.  Intermittent, low dose carbon monoxide exposure enhances survival and dopaminergic differentiation of human neural stem cells.

Authors:  Nanna Dreyer-Andersen; Ana Sofia Almeida; Pia Jensen; Morad Kamand; Justyna Okarmus; Tine Rosenberg; Stig Düring Friis; Alberto Martínez Serrano; Morten Blaabjerg; Bjarne Winther Kristensen; Troels Skrydstrup; Jan Bert Gramsbergen; Helena L A Vieira; Morten Meyer
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

9.  Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain.

Authors:  Ya-Qun Zhou; Dai-Qiang Liu; Shu-Ping Chen; Nan Chen; Jia Sun; Xiao-Mei Wang; Fei Cao; Yu-Ke Tian; Da-Wei Ye
Journal:  Acta Pharmacol Sin       Date:  2020-03-19       Impact factor: 6.150

10.  Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice.

Authors:  Karen Alejandra Méndez-Lara; David Santos; Núria Farré; Sheila Ruiz-Nogales; Sergi Leánez; José Luis Sánchez-Quesada; Edgar Zapico; Enrique Lerma; Joan Carles Escolà-Gil; Francisco Blanco-Vaca; Jesús María Martín-Campos; Josep Julve; Olga Pol
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.